{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:42:39Z","timestamp":1790700159631,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T00:00:00Z","timestamp":1552694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There is emerging evidence for the role of posaconazole in the management of Aspergillus-related cystic fibrosis (CF) lung disease. The tolerability and efficacy of posaconazole in paediatric CF is not well established. We report a prospective study over a fifty-three month period evaluating the safety, tolerability, and efficacy of posaconazole in pediatric CF. Fourteen children (seven males, median age 13 years, range 3\u201317 years) received a total of twenty-three courses of posaconazole (13 oral suspension and 10 tablet formulation). Of these patient episodes, nine received posaconazole for emerging or active allergic bronchopulmonary aspergillosis (ABPA) and two required a combination of posaconazole and systemic corticosteroids for difficult-to-treat ABPA. A subgroup of patients (n = 12) with persistent isolates of Aspergillus fumigatus, in the absence of serological markers of ABPA, received posaconazole monotherapy for pulmonary exacerbations not responding to conventional broad-spectrum antibiotic treatment. Posaconazole levels, full blood count, electrolytes, and liver function were monitored on day 7 of treatment and then monthly. Posaconazole was well tolerated in all but three patients. Therapeutic plasma levels &amp;gt;1\u00a0mg\/l were achieved in all receiving the tablet formulation in comparison to 60% on the liquid preparation. There was a modest but significant improvement in FEV1 (% predicted) demonstrated for the cohort as a whole (p = 0.015) following posaconazole therapy. Posaconazole is well tolerated in children as young as six years old, improvements in lung function are observed, and therapeutic plasma levels are readily achieved in patients taking the tablet formulation and in adherent patients taking the liquid formulation.<\/jats:p>","DOI":"10.1093\/mmy\/myz015","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T04:21:22Z","timestamp":1550463682000},"page":"11-21","source":"Crossref","is-referenced-by-count":24,"title":["Posaconazole therapy in children with cystic fibrosis and Aspergillus-related lung disease"],"prefix":"10.1093","volume":"58","author":[{"given":"Deepa","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Respiratory Sciences, NIHR Biomedical Research Centre (Respiratory theme) and Institute for Lung Health, University of Leicester, Leicester, United Kingdom"},{"name":"Department of Paediatric Respiratory Medicine, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Popple","sequence":"first","affiliation":[{"name":"Department of Paediatric Respiratory Medicine, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Claydon","sequence":"first","affiliation":[{"name":"Department of Paediatric Respiratory Medicine, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah E","family":"Modha","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erol A","family":"Gaillard","sequence":"first","affiliation":[{"name":"Department of Respiratory Sciences, NIHR Biomedical Research Centre (Respiratory theme) and Institute for Lung Health, University of Leicester, Leicester, United Kingdom"},{"name":"Department of Paediatric Respiratory Medicine, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,16]]},"reference":[{"key":"2020041602155789900_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.biocel.2014.03.001","article-title":"Review: Fungi in the cystic fibrosis lung: bystanders or pathogens","volume":"52","author":"Chotirmall","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"2020041602155789900_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2013.02.003","article-title":"What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis","volume":"12","author":"Liu","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2020041602155789900_bib3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/mmy\/myv119","article-title":"Chronic Aspergillus fumigatus colonization of the paediatric cystic fibrosis airway is common and may be associated with a more rapid decline in lung function","volume":"54","author":"Saunders","year":"2016","journal-title":"Med Mycol"},{"key":"2020041602155789900_bib4","doi-asserted-by":"crossref","first-page":"843763","DOI":"10.1155\/2011\/843763","article-title":"Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis","volume":"2011","author":"Knutsen","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"2020041602155789900_bib5","first-page":"37","article-title":"Diagnosing allergic bronchopulmonary aspergillosis in children with cystic fibrosis","volume":"10","author":"Thia","year":"2009","journal-title":"Paedri Respir Rev"},{"key":"2020041602155789900_bib6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1378\/chest.130.1.222","article-title":"Aspergillus spp. bronchitis in cystic fibrosis","volume":"130","author":"Shoseyov","year":"2006","journal-title":"Chest"},{"key":"2020041602155789900_bib7","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1469-0691.2010.03429.x","article-title":"Aspergillus fumigatus colonisation in cystic fibrosis: implications for lung function","volume":"17","author":"De Vrankrijker","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2020041602155789900_bib8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2013.04.007","article-title":"Novel immunological classification of aspergillosis in adult cystic fibrosis","volume":"132","author":"Baxter","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2020041602155789900_bib9","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/cea.12333","article-title":"Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis: a systematic review","volume":"44","author":"Moreira","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"2020041602155789900_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jcf.2012.09.007","article-title":"Subtherapeutic itraconazole and voriconazole levels in children with cystic fibrosis","volume":"12","author":"Bentley","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2020041602155789900_bib11","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/jac\/dks160","article-title":"High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR\/L98H, in a French cohort of patients with cystic fibrosis","volume":"67","author":"Morio","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020041602155789900_bib12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.05077-11","article-title":"High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole","volume":"56","author":"Burgel","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020041602155789900_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jcf.2005.05.019","article-title":"Voriconazole therapy in children with cystic fibrosis","volume":"4","author":"Hilliard","year":"2005","journal-title":"J Cyst Fibros"},{"key":"2020041602155789900_bib14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ppul.20656","article-title":"Factors effecting impact of A. fumigatus sensitisation in cystic fibrosis","volume":"42","author":"Kanthan","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"2020041602155789900_bib15","doi-asserted-by":"crossref","first-page":"e36077","DOI":"10.1371\/journal.pone.0036077","article-title":"Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomised, placebo-controlled pilot study","volume":"794","author":"Aaron","year":"2012","journal-title":"PLoS One"},{"key":"2020041602155789900_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2020041602155789900_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2710.2009.01055.x","article-title":"Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers","volume":"34","author":"Moton","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"2020041602155789900_bib18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tid.12497","article-title":"Posaconazole in lung transplant recipients: use, tolerability, and efficacy","volume":"18","author":"Robinson","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"2020041602155789900_bib19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/myc.12152","article-title":"Chronic pulmonary aspergillosis","volume":"57","author":"Schweer","year":"2014","journal-title":"Mycoses"},{"key":"2020041602155789900_bib20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"2020041602155789900_bib21","first-page":"BSOP 57","article-title":"Investigation of broncholveolar lavage, sputum, and associated specimens","author":"Health Protection Agency","year":"2004","journal-title":"National Standard Method"},{"key":"2020041602155789900_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/jof3020027","article-title":"MIC distributions and evaluation of fungicidal activity for amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin and 20 species of pathogenic filamentous fungi determined using CSLI broth microdiluation method","volume":"3","author":"Borman","year":"2017","journal-title":"J Fungi"},{"key":"2020041602155789900_bib23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1345\/aph.1R775","article-title":"Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer","volume":"47","author":"Bernardo","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2020041602155789900_bib24","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020041602155789900_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"2020041602155789900_bib26","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1002\/cptx.47","article-title":"Quantification of serum voriconazole, isuvuconazole and posaconazole by Liquid Chromatography Tandem Mass Spectrometry (LC-MS\/MS)","volume":"76","author":"Smith","year":"2018","journal-title":"Curr Protoc Toxicol"},{"key":"2020041602155789900_bib27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.diagmicrobio.2008.06.018","article-title":"Serological diagnosis of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis through the detection of immunoglobulin G to Aspergillus fumigatus","volume":"62","author":"Barton","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020041602155789900_bib28","volume-title":"British National Formulary","author":"Joint Formulary Committee","edition":"70"},{"key":"2020041602155789900_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/14787210.2018.1490177","article-title":"Posaconazole in immunocompromised pediatric patients","volume":"16","author":"Vicenzi","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2020041602155789900_bib30","doi-asserted-by":"crossref","first-page":"e02061-17","DOI":"10.1128\/AAC.02061-17","article-title":"Posaconazole tablets in real-life lung transplantation: Impact on exposure, drug-drug interactions, and drug management in lung transplant patients, including those with cystic fibrosis","volume":"62","author":"Launay","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041602155789900_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/FTD.0000000000000371","article-title":"Comparing azole plasma trough levels in lung transplant recipients: percentage of therapeutic levels and intrapatient variability","volume":"39","author":"Stelzer","year":"2017","journal-title":"Ther Drug Monit"},{"key":"2020041602155789900_bib32","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1128\/AAC.00424-16","article-title":"Pharmacokinetics of posaconazole suspension in lung transplant patients with and without cystic fibrosis","volume":"60","author":"Zhang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041602155789900_bib33","author":"Summary of product characteristics \u2013 Noxafil (posaconazole) 100\u00a0mg gastro-resistant tablets"},{"key":"2020041602155789900_bib34","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00222-12","article-title":"Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension","volume":"56","author":"Krishna","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041602155789900_bib35","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041602155789900_bib36","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/AAC.02448-13","article-title":"Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects","volume":"58","author":"Kraft","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041602155789900_bib37","first-page":"376287","article-title":"Use of nebulised amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis","author":"Proesmans","year":"2010","journal-title":"Int J Pediatr"},{"key":"2020041602155789900_bib38","first-page":"CD002204","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"11","author":"Elphick","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2020041602155789900_bib39","article-title":"Posaconazole administration in hospitalized children in the United States","author":"Lavigne","year":"2018","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/58\/1\/11\/33046960\/myz015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/58\/1\/11\/33046960\/myz015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T06:17:38Z","timestamp":1587017858000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/58\/1\/11\/5381954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,3,16]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myz015","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,3,16]]}}}